Japan's top drugmaker appoints first foreign boss

Japan's top drugmaker said Saturday it had picked a GlaxoSmithKline executive as its next president in a rare example of overseas head-hunting by a major Japanese firm.

The board of directors at Takeda Pharmaceutical, which has been active in foreign acquisitions in recent years, approved 47-year-old French Christophe Weber, as and candidate as the next chief executive.

He will be the first non-Japanese chief in 230 years of history at the company based in western Japan's Osaka.

Weber will join Takeda to take the role of chief operating officer by April 2014 and is expected to become president upon approval at a general meeting of shareholders in June, Takeda said in a statement.

Current president and chief executive Yasuchika Hasegawa is expected to become chairman and chief executive.

"We have extremely high expectations for Mr Weber's contributions to further enhance and accelerate the implementation of Takeda's global strategy," Hasegawa said in the statement.

Weber, educated at the University of Lyon, has held various positions at GSK in Europe, United States and the Asia-Pacific region.

Takeda operates in more than 70 countries after its 2011 acquisition of major Swiss rival Nycomed for $14 billion.

There are only a handful of foreign chiefs at leading Japanese companies. Carlos Ghosn, the of French auto group Renault who also heads Nissan Motor, is one of the most prominent.

add to favorites email to friend print save as pdf

Related Stories

Japanese firm buys US pharmaceutical company

Oct 05, 2012

(AP)—A Japanese pharmaceutical company is acquiring LigoCyte Pharmaceuticals in a $60 million deal to expand its vaccine division, Takeda Pharmaceutical Co. announced.

US drug firm Mylan to buy Indian firm for $1.6 bn

Feb 27, 2013

US generic drugs specialist Mylan said Thursday it would buy a unit of India's pharma firm Strides Arcolab for $1.6 billion, boosting its presence in the high-growth injectable drugs market.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments